Four mutations in the porphobilinogen deaminase gene in patients with acute intermittent porphoria

Gunnel Lundin, Jamileh Hashemi, Ylva Floderus, Stig Thunell, Erling Sagen, Astrid Lægreid, Wassif Wassif, Timothy Peters, Maria Anvret

Abstract
We have detected four different mutations in the porphobilinogen deaminase (PBGD) gene in acute intermittent porphoria (AIP) families from England, Norway, and Sweden. A splicing mutation in the first position of intron 1 (Int8 +1) was found in a family from England and a missense mutation in exon 12 (Glu250) was detected in a Norwegian family. Two mutations were identified in Swedish families, one splicing mutation in the first position of intron 3 (Int3 +1) and one missense mutation in exon 8 (Pro116).

(Materials and methods)

Fifty-nine mutations have been published in the porphobilinogen deaminase (PBGD; hydroxymethylbilane synthase, EC 4.3.1.8) gene associated with the autosomal dominant disease acute intermittent porphoria (AIP).\textsuperscript{1-10} PBGD is the third enzyme involved in haem synthesis, and AIP patients have a partial deficiency of the enzyme activity. When the demand for haem is increased, for example by alcohol or drug usage, the precursors ALA (δ-aminolevulinic acid) and PBG (porphobilinogen) accumulate in tissues and are probably responsible for the toxic effects in the neuropsychiatric porphorias. AIP seldom presents before puberty, many carriers are asymptomatic, and the disease can often be difficult to diagnose. The symptoms are varied with sometimes severe attacks of abdominal pain, paralysis, mental disturbances, and autonomic dysfunction.\textsuperscript{11}

The PBGD gene spans over 10 kb and comprises 15 exons. Mutations have been reported in all regions of the gene except in exons 2 and 11. The hot spots for mutations are exons 10 and 12. In Swedish families, six mutations have been found previously, one in exon 8 (Arg116), four in exon 10 (Arg167, Arg173, Trp198, and Arg203), and one, a splicing mutation, at the border of intron 9 and exon 10.\textsuperscript{11,12} The mutation affecting Trp198 in exon 10 originates from Årejög in northern Sweden and is the most common mutation among Swedish AIP patients.\textsuperscript{12}

(Materials and methods)

PATTERNS
Genomic DNA from one Norwegian, one English, and two Swedish AIP families were investigated.

The Norwegian family belongs to a large kindred originating from the district of Trøndelag in central Norway. A total of 28 family members were included in the study, 22 unaffected subjects and six gene carriers. The biochemical findings and linkage analysis have previously been described.\textsuperscript{14} Seven subjects selected from a large, well characterised English family were investigated. Three of them were diagnosed as AIP patients and three as unaffected. One family member was a possible gene carrier and treated as being at risk of AIP, though she had equivocal PBGD enzyme activity and had no AIP symptoms.\textsuperscript{15} The two Swedish families comprised 11 AIP carriers, 10 unaffected subjects, and two additional cases, for whom the results of the conventional diagnostic procedure were inconclusive.

The diagnosis of AIP was established or excluded by family history, clinical symptoms, and biochemical analyses, including porphobilinogen deaminase activity in erythrocytes and urinary excretion of porphobilinogen and δ-aminolaevulinic acid.

Primer used for exon amplification of the PBGD gene before single stranded sequencing

Exon 1 NEF-123,F Int1,128,R
Exon 3 Int2,F
Int3,R
Exon 4 Int3,F
Int4,R
Exon 5 JS39 JS5
Exon 8 JS109
Exon 9 Int8K
Int9,R
Exon 10 PHI10
Int11,F
Exon 14 Int13,F
Int14,R

DNA SEQUENCING

Genomic DNA was investigated by single stranded sequencing of exons 1, 3, 4, 5, 8, 9, 10, 12, and 14 in the PBGD gene. Primers for exon amplification were designed 52–86 bases from the exon/intron border (table).

The first PCR amplification was performed in 10 mmol/l Tris-HCl buffer, pH 8.8, containing 50 mmol/l KCl, 1.5 mmol/l MgCl2, 0.1% Triton X-100, 150 μmol/l of each dNTP, 25 pmol of each primer, 0.4 units of Dyanazyme (Finnzymes Oy), and 100 ng template DNA in
exon 8 (Pro<sup>19</sup>). The splicing mutation Int3 + 1 abolishes a cleavage site for the restriction enzyme BstNI. A 608 bp fragment was amplified and the normal allele was cleaved by BstNI into four fragments of 381, 82, 75, and 70 bp. The mutated allele, on the other hand, created only three fragments of 451, 82, and 75 bp. The fragments were visualised on a 2% NuSieve agarose gel (fig 1A).

The mutation in exon 8 (Pro<sup>19</sup>) created a cleavage site for the restriction enzyme XmnI. After PCR amplification of a 765 bp fragment, the mutated allele was cleaved into two fragments of 412 and 353 bp. These fragments were separated on a 1% agarose gel (fig 1B).

**Results**

Four new mutations have been found in the PBGD gene in one Norwegian, one English, and two Swedish families with AIP, hitherto uninvestigated (fig 2).

**SPlicing MUTATIONS**

Two splicing mutations were detected, one at the exon 3/intron 3 border and the other at the exon 8/intron 8 border. The mutation found in the first position of intron 8 (Int8 + 1), a G to T substitution, was found in a large English family (fig 2B). One of the members of this family had an uncertain AIP diagnosis, and carrier status could now be established.

The other splicing mutation, a G to A substitution in the first position of intron 3 (Int3 + 1), was found in a Swedish family with five AIP patients, one inconclusive, and four unaffected family members (fig 2C). This mutation can be detected by cleavage with the restriction enzyme BstNI (fig 1A).

**GLu<sup>250</sup>**

In a large Norwegian family with six AIP patients and 22 unaffected family members, a mutation was found in exon 12. This G to C substitution in position 748 converts Glu<sup>250</sup> to Ala (fig 2D). A mutation in this position has previously been reported in two unrelated families. In these families, however, the substitution was G to A, changing glutamine to lysine. The mutation was confirmed by allele
Four mutations in the porphobilinogen deaminase gene in patients with acute intermittent porphyria

This work was supported by grants from the Swedish Medical Research Council No 9108 (MA), and Torsten and Ragnar Söderberg Foundation (MA).


Discussion
Many mutations associated with AIP have been detected in the PBGD gene, including deletions, insertions, missense, nonsense, and splicing mutations. The mutations are scattered throughout the gene, but nearly half of them are found in exons 10 and 12. Only exons 2 and 13 have no reported mutations. In this paper, we present four new mutations in the PBGD gene. Two of these are splicing mutations in the first position of an intron (Int3 + 1 and Int8 + 1), and the other two are missense mutations affecting a single amino acid (Pro19 and Glu250). In exon 8, only two mutations were previously reported, altering the same amino acid (Arg185) to tryptophan or glutamine18,10,13; the mutation we have found affecting Pro111 is close to this site. The amino acids coded for by exon 8 are situated close to the active site of the enzyme, connecting domains 1 and 2.16 Changes in this part are likely to impair enzyme activity.

Fifteen base changes have been detected in exon 12 associated with AIP, 10 of them located between codons Leu245 and Leu257 in the last third of the exon.14,9,10,17-19 Consequently the mutation that changes Glu250 to Ala is within one of the hot spot regions for PBGD mutations.

The splicing mutations Int3 + 1 and Int8 + 1 both affect the splice donor site, which probably results in defective splicing.

It is of great benefit to AIP families when the actual mutation in the family is detected. This will not only identify family members with latent porphyria, but unaffected members can also be distinguished with confidence.20 Definitive assignment of AIP status makes it unnecessary for previously equivocal carriers to follow restrictions to prevent AIP attacks and avoids the need for family screening of future generations. In this study we have established carrier status in three subjects where the biochemical analyses were equivocal. In addition to mutations in the PBGD gene itself, there is a possibility of alterations in the regulation of enzyme activity being responsible for the disease and, in that case, the gene promoter regions should also be investigated.
Four mutations in the porphobilinogen deaminase gene in patients with acute intermittent porphyria.

G Lundin, J Hashemi, Y Floderus, S Thunell, E Sagen, A Laegreid, W Wassif, T Peters and M Anvret

J Med Genet 1995 32: 979-981
doi: 10.1136/jmg.32.12.979

Updated information and services can be found at:
http://jmg.bmj.com/content/32/12/979

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/